Herein, we demonstrated by Ussing chamber technique that male mice administered 1 g/kg 1,25(OH) 2D3 sc daily for 3 days exhibited increased duodenal calcium absorption, which was abolished by concurrent intravenous injection of recombinant mouse FGF-23. This FGF-23 administration had no effect on the background epithelial electrical properties, i.e., short-circuit current, transepithelial potential difference, and resistance. Immunohistochemical evidence of protein expressions of FGFR isoforms 1-4 in mouse duodenal epithelial cells suggested a possible direct effect of FGF-23 on the intestine. This was supported by the findings that FGF-23 directly added to the serosal compartment of the Ussing chamber and completely abolished the 1,25(OH) 2D3-induced calcium absorption in the duodenal tissues taken from the 1,25(OH) 2D3-treated mice. However, direct FGF-23 exposure did not decrease the duodenal calcium absorption without 1,25(OH) 2D3 preinjection. The observed FGF-23 action was mediated by MAPK/ERK, p38 MAPK, and PKC. Quantitative real-time PCR further showed that FGF-23 diminished the 1,25(OH) 2D3-induced upregulation of TRPV5, TRPV6, and calbindin-D 9k, but not PMCA1b expression in the duodenal epithelial cells. In conclusion, besides being a phosphatonin, FGF-23 was shown to be a novel calcium-regulating hormone that acted directly on the mouse intestine, thereby compromising the 1,25(OH) 2D3-induced calcium absorption.
FGF-23 is part of the bone-kidney-parathyroid endocrine axis, in which 1,25(OH) 2 D 3 induces FGF-23 secretion from bone. FGF-23 subsequently suppresses the productions of 1,25(OH) 2 D 3 and PTH in the kidney and parathyroid gland, respectively (29) . Some hereditary and acquired diseases, e.g., autosomal dominant hypophosphatemic rickets/osteomalacia, tumor-induced osteomalacia, and X-linked hypophosphatemic rickets, result from abnormally high circulating FGF-23 activity. Dysregulation of FGF-23 action is also evident in various pathological conditions, such as chronic metabolic acidosis and chronic kidney disease (11, 20) .
Once secreted from osteoblasts and osteocytes, FGF-23 exerts its phosphaturic action in the renal proximal tubular cells via the FGF receptor (FGFR)/Klotho coreceptor complex, thereby downregulating Na ϩ -dependent phosphate transporter (NPT)-2a and NPT-2c expression (14) . Its intracellular signaling in renal epithelial cells is conveyed through a number of pathways, e.g., mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), p38 MAPK, phosphoinositide 3-kinase (PI3K)/Akt, and protein kinase C (PKC) (12, 13, 43) . FGF-23 also downregulates renal 25-hydroxyvitamin D 1␣-hydroxylase (1-OHase; also known as Cyp27b1) and upregulates 24-hydroxylase (24-OHase, Cyp24a1), which are important enzymes for production and inactivation of 1,25(OH) 2 D 3 , respectively, thereby reducing circulating levels of 1,25(OH) 2 D 3 (35, 42) . Since 1,25(OH) 2 D 3 is the cardinal regulator of intestinal calcium absorption, and since there is a strong link between 1,25(OH) 2 D 3 and calcium-phosphate homeostasis (for reviews see Refs. 10 and 30) , it is probable that FGF-23 not only regulates phosphate metabolism but may also inhibit the 1,25(OH) 2 D 3 -induced intestinal calcium transport. In other words, besides being a phosphatonin, FGF-23 may also act as a calcium-regulating hormone to modulate intestinal calcium absorption. In addition to its indirect action by lowering plasma 1,25(OH) 2 D 3 levels, we hypothesized that FGF-23 could directly regulate calcium transport in intestinal epithelial cells, which have been reported to express FGFR mRNA (16) .
In humans and rodents, 1,25(OH) 2 D 3 enhances transcellular active calcium transport especially in duodenal villous epithelial cells (5, 22) . This transport mechanism is a three-step, metabolically energized process consisting of 1) apical calcium uptake via the transient receptor potential cation channel subfamily V (TRPV)-5 and -6, 2) cytoplasmic translocation by calcium-binding protein calbindin-D 9k , and 3) basolateral extrusion by plasma membrane Ca 2ϩ -ATPase (PMCA)-1b (8, 22) . A small proportion of the cytoplasmic calcium may be extruded via the basolateral Na ϩ /Ca 2ϩ exchanger (NCX)-1, the activity of which is ϳ5-fold lower than that of PMCA 1b (15) . The expressions of the major calcium-transporting proteins are strongly upregulated by 1,25(OH) 2 D 3 (10) . Therefore, it is reasonable to postulate that FGF-23 can suppress the 1,25(OH) 2 D 3 -induced upregulation of the intestinal calcium transporter gene expression. Thus, the objectives of the present study were 1) to demonstrate that FGF-23 administration could abolish the increase in duodenal calcium transport in 1,25(OH) 2 D 3 -treated mice; 2) to investigate whether duodenal tissue directly responded to FGF-23; 3) to determine possible signaling pathways of FGF-23 in the mouse duodenum by using various pharmacological antagonists; and 4) to demonstrate the expression of calcium transporter genes in the duodenal epithelial cells of 1,25(OH) 2 D 3 -and FGF-23-treated mice.
MATERIALS AND METHODS

Animals.
Male ICR mice (Mus musculus; 7 wk old, weighing 30 -40 g) were obtained from the National Laboratory Animal Centre, Thailand. Mice were acclimatized for 7 days before start of the (25, 33) . The vehicle-treated mice (control) were injected with 3 ml/kg 9:1 propylene glycol-ethanol sc [for 1,25(OH) 2D3 preparation] and 1 ml/kg 0.9% NaCl iv (for FGF-23 preparation). The 1,25(OH) 2D3-treated mice were also injected with the vehicle of FGF-23. In one experiment, mice were injected with 140 g/kg FGF-23 alone.
To determine whether murine intestine could directly respond to FGF-23, duodenal tissues taken from normal mice were subjected to immunohistochemical analyses of FGFR and Klotho expression. FGF-23 mRNA expression was also investigated in various tissues, e.g., small and large intestine, tibia, femur, spleen, liver, kidney, brain, and lung, to reveal the possible sources of circulating FGF-23 in mice. Thereafter, duodenal calcium flux and epithelial electrical properties were determined by Ussing chamber technique in FGF-23-exposed duodenal tissues. Recombinant mouse FGF-23 was added directly into the mucosal or serosal sides of the chamber to obtain a final concentration of 10, 20, or 40 ng/ml (38, 43) . In this Ussing chamber experiment (Fig. 1B) , duodenal tissues were obtained from vehicletreated (3 ml/kg 9:1 propylene glycol-ethanol sc; control group) or 1 g/kg sc 1,25(OH)2D3-treated mice (at 72, 48, and 24 h prior to tissue collection).
Although subcutaneous 1,25(OH)2D3 administration efficiently increases circulating 1,25(OH)2D3 level (40) , a number of studies also used the intraperitoneal route for systemic 1,25(OH)2D3 administration (1, 9) . Therefore, in some experiments (Fig. 1C ), mice were injected intraperitoneally with 1 g/kg 1,25(OH)2D3 or its vehicle at 52, 28, and 4 h prior to tissue collection to confirm that FGF-23 could also suppress the action of 1,25(OH)2D3 administered via the intraperitoneal route. Finally, calcium flux was measured in 10, 20, or 40 ng/ml FGF-23-exposed duodenal tissues from untreated normal mice to determine whether the direct effect of FGF-23 on mouse duodenum could be observed without pretreatment with 1,25(OH)2D3 (timeline diagram not shown).
In the last series of experiments (Fig. 1B) , all mice were injected with 1 g/kg 1,25(OH)2D3 sc at 72, 48, and 24 h before tissue collection. Calcium flux and electrical parameters were determined in the duodenal tissues directly exposed on the serosal side to 20 ng/ml recombinant mouse FGF-23. Some tissues were also exposed to various signal transduction inhibitors of effective concentrations (3, 4, 6, 17, 18, 31, 43) , as listed in Table 1 . The studied mediators, e.g., MAPK/ERK, Src, Janus kinase (JAK)-2 and PKC, are involved in FGFR signaling (12, 13, 44) . FGF-23 and/or signal transduction inhibitors were present in the Ussing chamber throughout the 10-min equilibration and 70-min 45 Ca exposure periods. A preliminary doseresponse study of each inhibitor was also performed (data not shown). As for the calcium transporter expression study by quantitative realtime PCR (qRT-PCR) (Fig. 1D) , duodenal epithelial cells were collected at 0, 3, 6, 12, and 24 h after a single injection of 2 g/kg Ussing chamber and epithelial electrical measurement. After a 1.5-cm median laparotomy was performed, duodenal tissue (0 -5 cm from the pylorus) was removed and cut longitudinally to expose the mucosa. The tissue was then mounted in an Ussing chamber with an exposure area of 0.3 cm 2 and bathed on both sides with 3 ml of normal bathing solution containing (in mmol/l) 118 NaCl, 4.7 KCl, 1.25 CaCl 2, 1.1 MgCl2, 23 NaHCO3, 12 D-glucose, and 2 mannitol (all purchased from Sigma, St. Louis, MO). The solution was continuously aerated with 5% CO 2 in 95% O2 at 37°C and had osmolality of ϳ290 mmol/kg H2O. Two epithelial electrical parameters, i.e., transepithelial potential difference (PD) and short-circuit current (Isc), were determined by Ag/AgCl half-cell connected to each hemichamber through a salt bridge (4 mol/l KCl in 4 g wt/vol agar). Two PD-sensing Ag/AgCl electrodes were placed adjacent to the mounted duodenal tissue and were connected to a preamplifier (model EVC-4000; World Precision Instruments, Sarasota, FL) and finally to PowerLab/4SP (AD Instruments, Colorado Springs, CO). The current-applying Ag/AgCl electrodes were placed at the distant end of each hemichamber to supply Isc, which was also measured by the EVC-4000/PowerLab system. Transepithelial resistance (TER) was calculated from PD and Isc by Ohm's equation (7).
Calcium flux measurement. Transepithelial calcium flux was determined by the modified method of Charoenphandhu et al. (7) . The tissue was first equilibrated in the chamber with physiological bathing solution for 10 min. Thereafter, the equilibrating solution was discarded, and the mucosal chamber was filled with bathing solution containing 45 Ca (0.45 Ci/ml; final specific activity of 360 mCi/mol; catalog no. NEZ013; PerkinElmer, Boston, MA). Unidirectional calcium flux (JH¡C; nmol·h
) from the hot side (H; mucosal side) to the cold side (C; serosal side) was calculated by Eqs. 1 and 2.
where RH¡C is the rate of tracer appearance in the cold side (cpm/h); SH is the specific activity in the hot side (cpm/nmol); A is the surface area of the tissue (cm 2 ); CH is the mean radioactivity in the hot side (cpm); and CTo is the total calcium content in the hot side (nmol).
To obtain R H¡C, six samples (100 l per sample) were collected from the cold side at 30, 40, 50, 60, 70, and 80 min after the hot side was filled with 45 Ca-containing solution. The same volumes were also aliquoted from the hot side. 45 Ca radioactivity in each sample was analyzed by liquid scintillation spectrophotometer (model Tri-Carb 3100; Packard, Meriden, CT). Linear regression was then performed [cold-side radioactivity (cpm) vs. time (h)], and the slope of the regression line was R H¡C. Total calcium concentration in bathing solution was analyzed by an atomic absorption spectrometer (model SpectrAA-300; Varian Techtron).
Since the duodenal voltage (PD)-dependent calcium transport was very small and could be considered negligible (data not shown), all experiments were performed under an open-circuit condition. In the absence of transepithelial calcium gradient (i.e., bathing solution in both hemichambers contained the same calcium concentration of 1.25 mmol/l), the measured transepithelial calcium flux represented the 
Cytoplasmic calcium transport
Calbindin-D9k AF136283 5=-TGCTGTTCCTGTCTGACTCCT-3= 180 5=-GGGGAACTCTGACTGAATCAG-3=
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Plasma membrane Ca 2ϩ -ATPase-1b (PMCA1b) NM_026482 5=-AATCCTGAGTGCTAATGGCG-3= 179 5=-CGGTGACGACATCATTCTCA-3=
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Fibroblast growth factor-23 (FGF-23) NM_022657 5=-ACATAGCTCCTGCTCACTC-3= 120 5=-TGTGTGTGAGTACAGATTCCCC-3=
Housekeeping gene
Hypoxanthine guanine phosphoribosyl transferase-1 (HPRT1) NM_013556 5=-GGACTGATTATGGACAGGACTG-3= 123 5=-ATCCAGCAGGTCAGCAAA-3= metabolically energized active calcium transport in mucosal-to-serosal (MS) direction (i.e., unidirectional calcium influx). Because the serosal-to-mucosal (SM) calcium fluxes of 1,25(OH) 2D3-treated mice (7.01 Ϯ 1.11 nmol·h Ϫ1 ·cm Ϫ2 ; 1 g·kg Ϫ1 ·day Ϫ1 sc for 3 days) were comparable to that of the vehicle-treated mice (5.85 Ϯ 0.54 nmol·h Ϫ1 ·cm Ϫ2 ; unpaired Student's t-test; n ϭ 5 per group, P ϭ 0.1885), the SM calcium flux measurement was not performed in the present study. In addition, our preliminary study in 1,25(OH)2D3-treated mice also demonstrated that the SM duodenal calcium flux (7.01 Ϯ 1.11 nmol·h Ϫ1 ·cm Ϫ2 ) was smaller than the MS calcium flux (17.91 Ϯ 1.17 nmol·h Ϫ1 ·cm Ϫ2 ; unpaired Student's t-test; n ϭ 5 per group, P Ͻ 0.001). Nevertheless, this measurable SM flux suggested that the unidirectional influx measured in our study was the sum of an active transcellular and a paracellular flux. A solvent drag component of unknown magnitude may be present in the measured unidirectional MS flux.
Tissue preparation and immunohistochemistry. Mouse duodenal tissues (ϳ5 cm) were dissected and rinsed off the luminal content, while the kidney and liver were also collected as positive controls for ␣-and ␤-Klotho expression, respectively. After removal of the adhering connective tissues, the tissues were preserved overnight at 4°C in 0.1 mol/l phosphate-buffered saline (PBS) containing 4% wt/vol paraformaldehyde (Merck, Darmstadt, Germany). Thereafter, they were dehydrated and cleared by graded ethanol and xylene, respectively. After being embedded in paraffin, the specimens were cut cross-sectionally into 5-m sections. Deparaffinized sections were incubated at 37°C for 30 min in antigen retrieval solution (0.01 mg/ml proteinase K, 50 mmol/l Tris·HCl, pH 8.0, and 5 mmol/l EDTA). Thereafter, the sections were incubated for 1 h with 3% vol/vol H 2O2 to inhibit endogenous peroxidase activity. Nonspecific bindings were blocked by 2-h incubation with 4% bovine serum albumin, 5% normal goat serum, and 0.1% vol/vol Tween-20 in PBS. To label the target proteins, the sections were incubated at 4°C overnight with rabbit polyclonal primary antibodies against FGFR-1 (1:200, catalog no. Total RNA preparation, quantitative real-time PCR and sequencing. Total RNA was collected from intestinal mucosal scrapings or homogenates from other organs (for FGF-23 expression study), such as tibia, Values are means Ϯ SE. PD, transepithelial potential difference; Isc, short-circuit current; TER, transepithelial resistance. The apical side was negative with respect to the basolateral side. Vehicle-treated mice were injected with 3 ml/kg 9:1 propylene glycol-ethanol sc [for 1,25(OH)2D3 preparation] and 1 ml/kg 0.9% NaCl iv (for FGF-23 preparation). 1 g/kg 1,25(OH)2D3 sc and 280 g/kg FGF-23 iv were administered at 72, 48, and 24 h prior to electrical parameter measurement. 1,25(OH)2D3-treated mice were also injected with the vehicle of FGF-23. femur, spleen, liver, kidney, brain, and lung, by using TRIzol reagent (Invitrogen), as described previously (7) . Purity of the total RNA was evaluated by NanoDrop 2000c spectrophotometer (Thermo Scientific, Waltham, MA) reading at 260 and 280 nm, the ratio of which ranged between 1.8 and 2.0. Total RNA (1 g) was reverse transcribed to cDNA with oligo(dT 20) primer and an iScript kit (Bio-Rad, Hercules, CA). Hypoxanthine guanine phosphoribosyltransferase (HPRT-1; a housekeeping gene) served as a control gene to check the consistency of the reverse transcription (%coefficient of variation of HPRT1 mRNA expression Ͻ 5%; n ϭ 6).
Primer sequences specific for the studied transcripts, namely TRPV5, TRPV6, calbindin-D 9k, PMCA1b, and FGF-23, are listed in Table 2 . Conventional PCR was performed for 36 cycles by MyCycler PCR system (Bio-Rad) with GoTaq Green Master Mix (Promega, Madison, WI), whereas qRT-PCR and melting curve analysis were performed by MiniOpticon real-time PCR system (Bio-Rad) with SsoFast EvaGreen Supermix (Bio-Rad). In some experiments, relative expression values of the studied genes over HPRT1 were calculated from the threshold cycle (C T) by using the 2 Ϫ⌬CT or 2 Ϫ⌬⌬CT methods (26) . PCR products were also visualized on a 1.5% agarose gel stained with 1.0 g/ml ethidium bromide under a UV transilluminator (Alpha Innotech, San Leandro, CA). After electrophoresis, the PCR products were purified from a gel with a Silica Bead DNA Gel Extraction Kit (catalog no. K0513; Fermentas, Glen Burnie, MD) and sequenced to confirm the correct amplicons by ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA). PCR experiments were performed in triplicate.
Statistical analysis. The results are expressed as means Ϯ SE. One-way analysis of variance with Dunnett's or Newman-Keuls posttest was used for multiple sets of data. Two sets of gene expression data were compared by one-tailed Mann-Whitney test. The level of significance for all statistical tests was P Ͻ 0.05. All data were analyzed by GraphPad Prism 5.0 for Mac OS X (GraphPad Software, San Diego, CA). Fig. 2 , the 3-day injection of 1 g/kg 1,25(OH) 2 D 3 sc significantly enhanced duodenal calcium transport (unidirectional calcium influx; MS direction) ϳ1.7-fold compared with vehicle treatment. Although 140 g/kg FGF-23 injection alone did not decrease the duodenal calcium transport, 140 and 280 g/kg FGF-23 injected via the tail vein concurrently with 1 g/kg 1,25(OH) 2 D 3 sc for 3 days totally abolished the 1,25(OH) 2 D 3 -enhanced calcium transport. Lower doses of FGF-23 had no such effect (Fig. 2) . FGF-23 administration did not alter the epithelial electrical properties, i.e., Isc, PD, and TER, in 1,25(OH) 2 D 3 -treated mice ( Table 3) . The results thus suggested that FGF-23 was a calcium-regulating hormone that antagonized 1,25(OH) 2 D 3 action in the mouse duodenum.
RESULTS
Intravenous FGF-23 administration abolished 1,25(OH) 2 D 3 -enhanced duodenal calcium absorption. As shown in
Duodenal epithelial cells abundantly expressed FGF-23 mRNA and FGFR proteins.
Although it was previously believed that circulating FGF-23 was secreted predominantly by osteoblasts and osteocytes, FGF-23 expression has also been reported in other tissues such as lung, thymus, and intestine (45) . We found that both small and large intestine, i.e., duodenum, jejunum, ileum, cecum, and colon, strongly expressed FGF-23 mRNA (Fig. 3A) . The FGF-23 expression was also observed in bone (tibia and femur; positive controls), spleen, liver, kidney, brain, and lung (Fig. 3A) . Interestingly, as determined by qRT-PCR, a single-dose injection of 2 g/kg 1,25(OH) 2 D 3 sc markedly enhanced the duodenal FGF-23 expression within 3 h, and the effect lasted at least 24 h after the single-dose injection (Fig. 3B) . Moreover, FGF-23 administration to 1,25(OH) 2 D 3 -treated mice further upregulated the duodenal FGF-23 mRNA expression at 3 h after injection, but not at 6 h (P ϭ 0.0589) or 12 h (P ϭ 0.2944) (Fig. 3C) . Melting curve analysis and amplicon sequencing confirmed the specificity of our PCR study. Our results thus suggested that, besides being the target of bone-derived endocrine FGF-23, the intestine might be able to respond to paracrine/autocrine FGF-23 as well.
Furthermore, immunohistochemical analysis was performed to visualize the duodenal expression of FGFR and coreceptor Klotho proteins. As illustrated in Fig. 4A, FGFRs 1-4 were expressed in the apical and basolateral membrane and in the cytoplasm of duodenal villous cells. However, ␣-and ␤-Klotho proteins, which were abundantly expressed in the kidney and liver (positive controls), respectively, were not expressed in the (Fig. 5) . None of the electrical parameters were changed by direct FGF-23 exposure (Table 4) . (Fig. 7) . None of these inhibitors affected the electrical parameters of FGF-23-treated duodenal tissues or the baseline calcium transport in FGF-23-untreated tissues (data not shown). Dimethyl sulfoxide (DMSO; final concentration of 0.3% vol/vol), used in the preparation of inhibitors, had no effect on the measured calcium transport (Fig. 7) .
Inhibitory effect of FGF-23 was mediated by MAPK/ERK
FGF-23 prevented 1,25(OH) 2 D 3 -induced upregulation of duodenal calcium transporter genes.
Prior to the investigation of FGF-23 effect on the 1,25(OH) 2 D 3 -induced calcium transporter gene expression, the time-dependent 1,25(OH) 2 D 3 action was first determined to find out the appropriate time points for tissue collection from 1,25(OH) 2 D 3 ϩFGF-23-treated mice. As depicted in Fig. 8, A-D , a single-dose injection of 2 g/kg 1,25(OH) 2 D 3 sc transiently upregulated TRPV5, TRPV6, calbindin-D 9k , and PMCA 1b mRNA expression in duodenal epithelial cells. Peak responses of TRPV5, TRPV6, and PMCA 1b expression were observed at 6 h after injection, whereas that of calbindin-D 9k was seen at 12 h (Fig. 8, A-D) . FGF-23 significantly decreased the 1,25(OH) 2 D 3 -induced upregulation of TRPV5 and TRPV6 at 6 or 12 h after injection, respectively (Fig. 8, E and F) . Moreover, the 1,25(OH) 2 D 3 -induced calbindin-D 9k expression was diminished by the intravenous FGF-23 administration at both time points (Fig. 8G ). FGF-23 had no effect on the 1,25(OH) 2 D 3 -induced PMCA 1b expression (Fig. 8H ).
DISCUSSION
As a multifunctional calcium/phosphate-regulating hormone, 1,25(OH) 2 D 3 exerts a plethora of genomic and nongenomic actions in the small intestine to increase calcium and phosphate Consistent with previous reports of FGFR expression in the small intestine, i.e., the duodenum and jejunum (16, 39) , the present immunohistochemical analyses showed FGFR 1-4 protein expression in the basolateral membrane of duodenal villous epithelial cells, thus confirming that these 1,25(OH) 2 D 3 -responsive duodenal cells acted as targets of FGF-23. Indeed, FGFR proteins were also observed in other duodenal cell compartments, i.e., cytoplasm and apical membrane, but their function is not well understood. Cytoplasmic FGFR proteins were previously reported in human mammary epithelial cells and might be important for the intracellular signaling of other FGFs, such as FGF-1 or -2, that could be produced intracellularly or internalized into the cells (49) . In addition, the expressions of receptor tyrosine kinases [e.g., FGFR and epidermal growth factor (EGF) receptors] in the apical membrane of small intestinal enterocytes have been reported before, and the intraluminal secretion of their ligands (e.g., basic FGFs and EGF) probably participated in intestinal cell proliferation and healing (27, 28, 37) . However, despite the presence of FGFRs Values are means Ϯ SE. The apical side was negative with respect to the basolateral side. Vehicle-treated mice were injected with 3 ml/kg 9:1 propylene glycol-ethanol sc, and 1,25(OH)2D3-treated mice were injected with 1 g/kg 1,25(OH)2D3 sc at 72, 48, and 24 h prior to electrical parameter measurement. Normal mice were treated with neither 1,25(OH)2D3 nor its vehicle. FGF-23 was directly added in Ussing chamber. M and S, mucosal and serosal exposure, respectively. One-way ANOVA with Dunnett's posttest was used to compare 1,25(OH)2D3-treated groups with vehicle-treated group. In normal mice, 0 ng/ml FGF-23 was the control group for statistical analysis. in the enterocytic apical membrane, the inhibitory action of FGF-23 on 1,25(OH) 2 D 3 -induced duodenal calcium absorption was likely to result from plasma FGF-23, since direct FGF-23 exposure on the mucosal side was without effect (Fig. 5) .
In the present study (35) reported that feeding vitamin D receptor (VDR) knockout mice a 2% wt/wt high-calcium diet for a week resulted in elevated serum total calcium levels and a 16-fold increase in the serum levels of FGF-23. Hence, in addition to serum phosphate and 1,25(OH) 2 D 3 , calcium may be another determinant of FGF-23 production in a VDR-independent manner (35) . On the basis of the present antagonistic effect of FGF-23 on the 1,25(OH) 2 D 3 -dependent intestinal calcium transport, we further postulated that FGF-23 was part of the negative feedback loop of the kidney-intestine-bone axis. Specifically, once the kidney produced 1,25(OH) 2 D 3 to enhance intestinal calcium absorption, an increase in circulating calcium in turn stimulated FGF-23 production and secretion from bone, and perhaps from the intestinal epithelial cells, to counterbalance 1,25(OH) 2 D 3 action. The intestine-derived FGF-23 production might indeed help fine-tune the 1,25(OH) 2 D 3 action at the target organ, thus preventing excessive intestinal absorption of calcium and/or phosphate. FGF-23 knockout mice, therefore, manifested both hypercalcemia and hyperphosphatemia (34, 48) .
The signal transduction of FGF-23 in the duodenal epithelial cells was initiated by binding of FGF-23 to FGFRs in the basolateral membrane; however, the precise FGFR subtypes responsible for such FGF-23 action need further study. Indeed, FGF-23 could activate the c-splice isoforms of FGFR 1-3 and FGFR 4, as determined by surface plasmon resonance and mitogenesis techniques (46) . Whether the obligatory coreceptor Klotho is also required to initiate intestinal FGFR signaling remains unknown. Since the duodenum did not express Klotho proteins, it is possible that the duodenal FGF-23/FGFR signaling was Klotho independent, similar to the inhibitory effect of FGF-23 on osteoblast differentiation and bone mineralization (29, 41) . Alternatively, duodenal FGFR might use the circulating form of Klotho, which is produced by cleavage of the transmembrane Klotho just above the plasma membrane of Klotho-producing cells, such as renal tubular cells (24) . Evidence supporting the role of Klotho in the duodenal response to FGF-23 was further provided by the report that Klotho knockout mice manifested increases in intestinal calcium absorption and duodenal mRNA expression of TRPV6 and calbindin-D 9k but not PMCA 1b (2) . In other words, the present study was a reversed scenario that, in the presence of FGF-23 (and Klotho), the 1,25(OH) 2 D 3 -induced increases in intestinal calcium absorption, and the expression of TRPV6 and calbindin-D 9k , but not PMCA 1b , were diminished. The subsequent intracellular signal transduction in the duodenal epithelial cells was found to be mediated by MAPK/ERK and p38 MAPK, similar to those reported previously in renal proximal and distal tubular cells, MC3T3.E1 osteoblast-like cells, parathyroid cells, and neonatal rat ventricular cardiomyocytes (12, 13, 32) . PKC also participated in the duodenal FGF-23 signal transduction. Other signaling pathways, e.g., JAK2 or PI3K, were not involved in the present inhibitory action of FGF-23.
Consistent with previous reports (10, 36) , at the molecular level, a single subcutaneous injection of 1,25(OH) 2 D 3 transiently upregulated the mRNA expression of the key duodenal calcium transporter genes, namely TRPV5, TRPV6, and calbindin-D 9k , which was inhibited by a concurrent intravenous FGF-23 injection. However, the 1,25(OH) 2 D 3 -induced expression of PMCA 1b mRNA encoding the key basolateral calcium transporter was not abolished by FGF-23. Similarly, NCX1 mRNA expression, which was also enhanced by 1,25(OH) 2 D 3 action, was not affected by FGF-23 (N. Charoenphandhu and J. Teerapornpuntakit, unpublished observation). Thus, FGF-23 appeared to predominantly regulate the genes for apical calcium entry and cytoplasmic calcium translocation, but not the basolateral calcium extrusion. However, further investigation is required to elucidate the underlying mechanism of the FGF-23-induced suppression of 1,25(OH) 2 D 3 effect in duodenal epithelial cells.
In conclusion, we have provided corroborative evidence, for the first time, that FGF-23 has a calcium-regulatory role of counterbalancing 1,25(OH) 2 D 3 -enhanced duodenal calcium absorption. To exert this inhibitory action, FGF-23 binds to FGFRs in the basolateral membrane of duodenal epithelial cells, thereby activating MAPK/ERK, p38 MAPK, and PKC cascades. Although the detailed molecular mechanism is unknown, FGF-23 eventually prevented the 1,25(OH) 2 D 3 -induced upregulation of TRPV5, TRPV6, and calbindin-D 9k , and diminished the stimulatory effect of 1,25(OH) 2 D 3 on duodenal calcium absorption. Thus, FGF-23 appears to be an important negative feedback regulator of the vitamin D endocrine system in the kidney-intestine-bone axis.
